Trials / Completed
CompletedNCT01679834
An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C
A Roche Project in Cooperation With the Bng (Association of German Resident Gastroenterologists) for Quality Assurance in the Dual- or Triple-therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa 2a (Pegasys) at Hepatology Centers
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,500 (estimated)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multicenter, observational study will assess the efficacy and the safety of Pegasys (peginterferon alfa 2a) in dual- or triple therapy in patients with chronic hepatitis C. Patients will receive Pegasys and/or ribavirin and/or a protease inhibitor according to local guidelines. Data will be collected for 96 weeks.
Conditions
Timeline
- Start date
- 2014-11-24
- Primary completion
- 2017-07-14
- Completion
- 2017-07-14
- First posted
- 2012-09-06
- Last updated
- 2018-03-01
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01679834. Inclusion in this directory is not an endorsement.